News
-
Senzer Pharmaceuticals said that it plans to launch its cannabinoid inhaler in the UK and elsewhere in Europe by the end of 2019 now that the device has received Class IIa Medical Device approval for the… Read more . . .
-
Russian biopharmaceutical company Generium JSC’s dornase alfa biosimilar inhalation solution has received marketing approval from Russian regulators for the treatment of cystic fibrosis, according to its partner Selexis, which developed the cell line. Genentech’s Pulmozyme dornase… Read more . . .
-
Inhalation Sciences AB (ISAB) has announced that former ExScale Bio CEO Manoush Masarrat, who has been a member of the ISAB board of directors since January 2019, will succeed Lena Heffler as ISAB CEO. In… Read more . . .
-
Canadian-based cannabis company TerrAscend has acquired exclusive distribution rights to Syqe Medical’s Syqe medical cannabis inhaler in Canada, the companies announced. The Syqe inhaler, which uses cartridges loaded with medical cannabis plant material, has been available… Read more . . .
-
Ruling on post-trial motions in a case in which a jury found in May 2019 that GSK had willfully infringed on a Vectura patent covering Ellipta, the presiding judge has upheld the jury’s award of… Read more . . .
-
Intranasal drug developer Optinose announced that it has issued $80 million in senior secured notes as part of a $150 million debt financing agreement with Pharmakon Advisors. The company plans to issue another $30 million in… Read more . . .
-
Satsuma Pharmaceuticals has announced an underwritten initial public offering of 5,500,000 shares of its common stock at $15.00 per share, with expected gross proceeds of $82.5 million. The underwriters of the offering also get a 30-day option to… Read more . . .
-
Inhaled insulin developer Dance Biopharm announced that it has signed an agreement with DarioHealth to integrate its smart soft mist inhaler into DarioHealth’s digital platform. The integration, which will allow patients using the SMI to get… Read more . . .
-
The US Patent Trial and Appeal Board (PTAB) has instituted an inter partes review of US Patent No. 9,211,253, “Nasal drug products and methods of their use.” That patent, which covers Opiant Pharmaceutical’s Narcan intranasal… Read more . . .
-
Santhera Pharmaceuticals has announced the publication of data from two Phase 1 studies of its POL6014 inhaled human neutrophil elastase (hNE) inhibitor in the Journal of Cystic Fibrosis. According to the company, inhalation of nebulized POL6014… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK